Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-551-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$74.91 million
Profitability
Miscellaneous
Employees1,065
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.20) by $0.47. The biopharmaceutical company earned $33.29 million during the quarter, compared to the consensus estimate of $21.60 million. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. Alnylam Pharmaceuticals's revenue was up 52.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.22) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
18 Wall Street analysts have issued 1-year target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $70.00 to $230.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $127.4444 in the next year. This suggests a possible upside of 84.9% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.
What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alnylam earnings and revenues beat estimates in the first quarter of 2019, owing to robust Onpattro sales. The company demonstrated good progress in global commercialization of Onpattro, continued success in R&D efforts with positive phase III results for givosiran, and a strong commitment to future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro in patients with cardiomyopathy. The company also expects to submit two NDAs (givosiran and inclisiran) in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, currently it depends heavily on Onpattro for growth, which is a concern. The company is heavily dependent on its partnerships for supporting operations and pipeline development activities. Shares of the company have outperformed the industry year to date." (5/8/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)
- 3. Needham & Company LLC analysts commented, "Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY." (9/13/2018)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
Media coverage about ALNY stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ) and Loxo Oncology (LOXO).
What other stocks do shareholders of Alnylam Pharmaceuticals own?
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
- Mr. Barry E. Greene, Pres (Age 56)
- Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
- Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
- Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.97%), Wellington Management Group LLP (13.92%), BlackRock Inc. (6.03%), Baillie Gifford & Co. (5.35%), Maverick Capital Ltd. (3.01%) and Morgan Stanley (1.15%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which major investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Tobam, Frontier Capital Management Co. LLC, Hsbc Holdings PLC, Sio Capital Management LLC, Pictet Asset Management Ltd., ArrowMark Colorado Holdings LLC and Royal London Asset Management Ltd.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include John Maraganore, Laurie Keating, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which major investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., FMR LLC, Wellington Management Group LLP, Maverick Capital Ltd., BlackRock Inc., Coronation Fund Managers Ltd., Charles Schwab Investment Management Inc. and SG Americas Securities LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $68.93.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $7.34 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.
What is Alnylam Pharmaceuticals' official website?
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
